Medicus Pharma (NASDAQ:MDCX) said it will participate in the BIO International Conference in San Diego from June 22 to 25.
The company’s chief medical officer, Dr Faisal Mehmud, will present updates on SkinJect, including Phase 2 data, FDA interactions and planned registrational strategy, as well as developments for Teverelix, including a Phase 2a endometriosis study designed to evaluate genomic profiling and hormonal modulation.